Dexcom
DXCM
$57.82
-1.28%
DexCom, Inc. is a leading healthcare company that designs and commercializes continuous glucose monitoring (CGM) systems for diabetic patients, operating within the medical devices industry. The company is a dominant market leader in the CGM space, distinguished by its focus on providing an alternative to traditional blood glucose meters and its strategic integration with insulin pumps for automated insulin delivery. The current investor narrative is centered on the company's ability to sustain its robust growth trajectory in a large and expanding diabetes care market, with recent attention focused on quarterly financial performance and its competitive positioning against other players in the diabetes management ecosystem.…
DXCM
Dexcom
$57.82
Investment Opinion: Should I buy DXCM Today?
Rating & Thesis: Hold. DexCom is a fundamentally strong company caught in a technical downtrend, creating a disconnect that warrants patience rather than immediate conviction. The lack of a clear analyst consensus target adds to the uncertainty, making a definitive Buy or Sell call premature at this juncture.
Supporting Evidence: The hold rating is supported by four key data points: 1) The forward P/E of 20.17x offers a more reasonable entry point than the trailing 30.97x, 2) Revenue growth remains robust at 13.12% YoY, 3) Profitability is improving dramatically with net margin expanding from 10.17% to 21.22% through FY2025, and 4) The PEG ratio of 0.66 suggests the growth story is not fully priced in. However, these positives are counterbalanced by the stock's 1-year decline of -12.68% and its position just 16% above the 52-week low.
Risks & Conditions: The two biggest risks are a break below the $54.11 support level, which would invalidate the technical stabilization thesis, and a deceleration in quarterly revenue growth below 10%. This Hold would upgrade to a Buy if the stock establishes a firm base above $60 and shows a sustained breakout above the $74.38 resistance on strong volume and earnings. It would downgrade to a Sell if QoQ revenue growth decelerates sharply or if the $54.11 support is decisively broken. Relative to its own growth trajectory, the stock appears fairly valued to slightly undervalued (per PEG), but relative to its battered price action, it presents a potential opportunity for patient investors.
Sign up to view all
DXCM 12-Month Price Forecast
DexCom presents a conflicted picture. Fundamentally, it is a high-quality growth company with strong margins and cash flow, trading at a PEG that suggests opportunity. Technically, it is broken, trading near 52-week lows with weak momentum. The neutral stance reflects this stalemate. The forward P/E of 20x prices in strong growth, leaving little room for error. The stance would upgrade to bullish on a confirmed technical reversal above $74 resistance accompanied by sustained double-digit revenue growth. It would turn bearish on a breakdown below $54 support or a material slowdown in the top-line growth rate to single digits. The base case of range-bound consolidation is the most probable near-term path.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dexcom's 12-month outlook, with a consensus price target around $75.17 and implied upside of +30.0% versus the current price.
Average Target
$75.17
16 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$46 - $75
Analyst target range
Analyst coverage for DXCM appears limited in the provided dataset, with only recent institutional rating actions listed and no explicit consensus price target, average target, or buy/hold/sell distribution provided. The recent institutional ratings show a predominantly bullish bias, with firms like Citigroup, BTIG, Truist Securities, Canaccord Genuity, Mizuho, and Wells Fargo maintaining 'Buy' or 'Overweight' ratings in Q1 2026, while Barclays holds an 'Underweight' stance. The absence of a quantified consensus target and the presence of both bullish and bearish ratings signals a degree of uncertainty and debate among analysts regarding the stock's near-term prospects, which can contribute to higher volatility as the market weighs competing narratives on growth sustainability and competitive pressures.
Bulls vs Bears: DXCM Investment Factors
The evidence presents a classic battle between strong fundamentals and weak technicals. The bull case is grounded in DexCom's demonstrable operational excellence: accelerating revenue, expanding margins, robust cash flow, and a PEG ratio signaling undervaluation. The bear case is equally compelling, driven by a severe price downtrend, high absolute valuation, and significant market underperformance. Currently, the bearish technical momentum and high short interest exert stronger near-term pressure on the stock. The single most important tension is whether the company's fundamental growth (13.12% YoY revenue, margin expansion) can overcome the market's skepticism and valuation compression before technical support at $54.11 fails. The resolution of this growth-versus-valuation debate will determine the stock's direction.
Bullish
- Strong Revenue Growth & Margin Expansion: Q4 2025 revenue grew 13.12% YoY to $1.26B, accelerating sequentially from Q1. Net margin expanded from 10.17% in Q1 to 21.22% in Q4, demonstrating significant operating leverage and pricing power.
- Undervalued PEG Ratio: The PEG ratio of 0.66, based on trailing P/E and growth, suggests the stock is undervalued relative to its earnings growth rate. This is a classic signal for growth-at-a-reasonable-price (GARP) investors.
- Robust Profitability & Cash Generation: The company generated $1.08B in TTM free cash flow and maintains a healthy 62.93% gross margin. This strong cash flow supports continued R&D, share buybacks ($312.8M in Q4), and provides a buffer against market volatility.
- Solid Balance Sheet & Financial Health: A current ratio of 1.88 and a manageable debt-to-equity of 0.51 indicate a low-risk financial structure. This provides strategic flexibility for investments and M&A without over-leveraging.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is down 12.68% over the past year and has underperformed the S&P 500 by -41.72%. Trading just 16% above its 52-week low of $54.11, it shows persistent bearish momentum and weak relative strength.
- High Valuation Multiples Despite Correction: Even after a significant drawdown, the trailing P/E of 30.97x and P/S of 5.56x remain elevated for a medical device company. This leaves the stock vulnerable to further multiple compression if growth expectations falter.
- Revenue Growth Deceleration Risk: While Q4 growth was 13.12%, sustaining this pace in a competitive and potentially saturated core market is a key challenge. Any miss against the analyst-estimated $8.6B in forward revenue could trigger a sharp re-rating.
- Lack of Clear Analyst Price Targets: The absence of a published consensus price target and average analyst target creates uncertainty and can contribute to higher volatility. The presence of an 'Underweight' rating (Barclays) highlights ongoing debate about the stock's prospects.
DXCM Technical Analysis
The stock is in a pronounced downtrend, evidenced by a 1-year price change of -12.68% and a 3-month decline of -16.00%. Currently trading at $61.35, the price sits just 16% above its 52-week low of $54.11 and 32% below its 52-week high of $89.98, indicating it is near the lower end of its annual range, which may suggest a potential value opportunity but also reflects significant bearish pressure. Recent momentum shows a slight deceleration in the sell-off, with a 1-month price change of -1.64%, which is less severe than the 3-month drop, hinting at a possible consolidation or stabilization phase after the sharper decline. The stock has demonstrated significant volatility, with a maximum drawdown of -38.75% over the period, and its relative strength metrics are deeply negative, showing underperformance of -41.72% versus the S&P 500 over the past year. Key technical levels are clearly defined, with the 52-week low of $54.11 acting as critical support; a sustained break below this level would signal a continuation of the downtrend, while resistance is established near the recent highs around $74.38 from late February, with a breakout above needed to suggest a trend reversal.
Beta
1.40
1.40x market volatility
Max Drawdown
-38.8%
Largest decline past year
52-Week Range
$54-$90
Price range past year
Annual Return
-33.2%
Cumulative gain past year
| Period | DXCM Return | S&P 500 |
|---|---|---|
| 1m | -8.1% | +7.7% |
| 3m | -17.4% | +9.7% |
| 6m | -0.4% | +11.3% |
| 1y | -33.2% | +27.3% |
| ytd | -13.1% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DXCM Fundamental Analysis
Revenue growth remains strong, with Q4 2025 revenue of $1.26 billion representing a 13.12% year-over-year increase, and sequential quarterly revenue has climbed from $1.04 billion in Q1 to the Q4 peak, indicating sustained demand acceleration. The company is solidly profitable, with Q4 2025 net income of $267.3 million and a net margin of 21.22%, while gross margin for the quarter was a healthy 62.93%, reflecting the company's pricing power and operational efficiency. Profitability has improved markedly through the year, as Q1 2025 net income was $105.4 million with a 10.17% net margin, demonstrating significant margin expansion driven by operating leverage. The balance sheet is healthy with a current ratio of 1.88 and a manageable debt-to-equity ratio of 0.51, while the company generated substantial free cash flow of $1.08 billion over the trailing twelve months, providing ample internal resources for growth and shareholder returns, as evidenced by a significant stock repurchase activity of $312.8 million in Q4 2025.
Quarterly Revenue
$1.3B
2025-12
Revenue YoY Growth
+0.13%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DXCM Overvalued?
Given the company's consistent profitability, the primary valuation metric is the P/E ratio. The trailing P/E stands at 30.97x, while the forward P/E is significantly lower at 20.17x, indicating the market expects substantial earnings growth in the coming year. Compared to its own historical range, the current trailing P/E of 30.97x is below the multi-quarter highs seen in 2024 (e.g., 91.91x in Q1 2024) but above the more recent low of 24.00x from Q4 2025, suggesting the valuation has compressed from prior peaks but may not yet be at a deep historical discount. The PEG ratio of 0.66, based on trailing metrics, implies the stock may be undervalued relative to its growth rate, a point of potential opportunity for growth investors.
PE
31.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -671x~231x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: DexCom's primary financial risk is its premium valuation, with a trailing P/E of 30.97x, which demands sustained high growth to justify. While margins are expanding, any deceleration in the 13%+ revenue growth rate could pressure the P/E multiple significantly. The company also faces concentration risk in the CGM market, where competitive and reimbursement pressures could emerge, though its strong 62.9% gross margin provides a cushion. The healthy balance sheet (D/E 0.51) and substantial FCF ($1.08B TTM) mitigate traditional financial risks, shifting focus to execution risks.
Market & Competitive Risks: The stock trades at a significant premium to many medical device peers based on P/E and P/S multiples, creating valuation compression risk if investor appetite for growth stocks wanes. Its high volatility (max drawdown -38.75%) and severe underperformance versus the S&P 500 (-41.72% over 1 year) indicate high sensitivity to market rotations away from growth. Recent news of cooling inflation may benefit rate-sensitive sectors, but DXCM's performance has been driven by company-specific concerns, suggesting competitive and execution risks are more immediate threats than macro factors.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth scare (e.g., quarterly revenue growth falling below 10%), increased competitive pressure leading to margin contraction, and a broader de-rating of growth stocks. This could trigger a cascade of analyst downgrades and force the stock to test and break its critical 52-week low support of $54.11. A realistic downside from the current price of $61.35 would be a decline of approximately 12% to that level, with the potential for an overshoot to the $50 range if sentiment turns severely negative, representing a peak loss of 18-20%.
FAQ
The key risks are, in order of severity: 1) Valuation & Growth Risk: The high P/E demands sustained double-digit growth; a slowdown could trigger severe multiple compression. 2) Technical & Sentiment Risk: The stock is in a deep downtrend (-12.68% 1-year) with high short interest (ratio 3.77), making it vulnerable to further selling pressure. 3) Competitive Risk: As the CGM market leader, it faces constant pressure from rivals like Abbott, which could impact pricing and market share. 4) Execution Risk: Any misstep in product launches, manufacturing, or navigating reimbursement policies could disrupt the growth trajectory and profitability evidenced by its 21.22% net margin.
The 12-month forecast is defined by three scenarios with a base case target of $65-$75 (50% probability). The bull case (30% probability) targets $85-$95, requiring a re-rating on accelerating growth and successful execution. The bear case (20% probability) sees a drop to $50-$58 if growth decelerates and support at $54 breaks. The base case is most likely, anticipating the stock consolidates and grinds higher as steady earnings growth of ~20% (implied by forward P/E) supports the price, but without a major multiple expansion. The key assumption for the base forecast is that quarterly revenue growth remains in the 12-14% range.
DXCM's valuation sends mixed signals. Based on traditional metrics, it appears expensive with a trailing P/E of 30.97x and a P/S of 5.56x. However, the more relevant forward P/E is 20.17x, reflecting expected earnings growth. The key metric is the PEG ratio of 0.66, which is calculated using the trailing P/E and implies the stock is undervalued relative to its growth rate. This suggests the market may be overly pessimistic. Compared to its own history, the P/E has compressed significantly from highs above 90x in early 2024. The valuation is fair to slightly undervalued for a company growing revenue at 13%+ with expanding margins, but it remains premium-priced, requiring continued execution.
DXCM is a good buy for patient, long-term investors who believe in the secular growth of the CGM market and can tolerate high volatility. The PEG ratio of 0.66 suggests the growth story is undervalued, and the forward P/E of 20.17x offers a more reasonable entry point. However, the stock is in a pronounced downtrend, down 12.68% over the past year and trading just 16% above its 52-week low, indicating significant bearish pressure. It is not a good buy for short-term traders or those sensitive to drawdowns, given its -38.75% maximum drawdown. A disciplined approach would be to initiate a small position on weakness, with plans to add on a confirmed breakout above $74 resistance.
DXCM is unequivocally suitable for a long-term investment horizon, with a suggested minimum holding period of 3-5 years. Its high volatility (beta implied by -41.72% relative underperformance), lack of a dividend, and current technical weakness make it a poor candidate for short-term trading. The investment thesis is based on the long-term secular growth of diabetes care and DexCom's leadership within it, which will take years to fully play out. Long-term investors can use periods of weakness, like the current one, to build a position in a high-quality company at a more reasonable valuation (PEG 0.66). Short-term traders face significant headwinds from the downtrend and lack of clear near-term catalysts.